SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

Mannatech Inc. ($MTEX) is currently trending with strong community interest, fueled by its notably low public float and increasing buying momentum. Traders are actively anticipating a significant breakout and a potential short squeeze, eyeing key price levels as volume continues to build.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is commanding market attention as a critical year-end deadline approaches for its Austin robotaxi service to operate without safety monitors, serving as a pivotal test for its AI and autonomous driving ambitions. The community is intensely divided; bulls foresee a significant rebound driven by anticipated breakthroughs in FSD and robotics, while bears highlight concerns over slowing EV demand, recent battery supply contract cuts, and a valuation heavily reliant on unproven future promises. With upcoming delivery reports also on the horizon, the market's focus remains squarely on these near-term developments to gauge the company's trajectory beyond its traditional automotive segment.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is a major talking point following a proposed business combination with Applied Digital's AI cloud division, ChronoScale, which aims to create an accelerated compute platform. The community is buzzing about this strategic pivot, with strong sentiment around its NVIDIA program acceptance and newly reduced share float amplifying expectations for significant future growth in the artificial intelligence space. Many believe the company is currently undervalued and poised for a substantial rally.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending as discussions intensify around its near-term regulatory decision for Relacorilant for Cushing's syndrome and the promising trial outcomes for its ovarian cancer and ALS programs. The community anticipates these pipeline advancements will unlock substantial future revenue, positioning the company for significant growth and prompting speculation about a potential short squeeze given its high short interest. This outlook is further supported by updated analyst price targets reflecting optimism about Corcept's expanding therapeutic impact.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending due to compelling preliminary Phase 3 trial data showing an 80% reduction in breast cancer recurrence, alongside a significant show of insider confidence with the Board extending share lock-ups until September 2026. This news has intensified community discussions around a potential short squeeze, given the stock's extremely low float and high cost to borrow, as investors anticipate substantial upside for this undervalued immunotherapy company.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics ($AQST) is trending as its PDUFA date for the needle-free Anaphylm oral epinephrine film approaches, fueling strong community anticipation of FDA approval. Investors are optimistic about its potential as a 'game-changing' alternative to current treatments, especially given the FDA's decision to forgo an Advisory Committee meeting. Despite market volatility and discussions surrounding short interest, many believe Anaphylm's convenience and broad applicability position AQST for significant market adoption post-approval.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem is currently a hot topic after discontinuing its RAMP 203 trial to focus on the promising VS-7375 program, a strategic pivot that followed strong Q3 revenue beats. However, a recent $90 million public offering has sparked considerable frustration and debate among investors, many of whom feel betrayed by the dilution despite the company's stated financial position. This has led to accusations of market manipulation and amplified concerns about short selling within a volatile biotech sector.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) experienced a sharp pullback following the CME Group's increase in margin requirements for silver futures, triggering forced liquidations. This move has ignited intense community debate, with many investors citing market manipulation and a disconnect between paper and physical silver prices, particularly in light of impending Chinese export restrictions. Despite the volatility, many bulls are calling this a buying opportunity due to perceived supply shortages and increasing industrial demand, while others anticipate further declines and lament potential 'bag holding.'

FONAR Corp. engages in the design, manufacture, sale, and servicing of magnetic resonance imaging scanners. It operates through Manufacturing and Servicing of Medical Equipment, and Management of Diagnostic Imaging Center segments. The Manufacturing and Servicing of Medical Equipment segment promotes its product, Fonar Upright MRI. The Management of Diagnostic Imaging Center segment offers management, administrative, billing and collection services, office space, equipment, repair, maintenance service and clerical, and non-medical personnel to medical providers through its subsidiary, Health Management Corp. of America. The company was founded by Raymond V. Damadian on July 17, 1978 and is headquartered in Melville, NY.

Fonar Corp.

Fonar (FONR) is trending as the company announced a definitive agreement to be taken private by a group led by its CEO at $19.00 per share. This proposed acquisition price has sparked considerable debate among the community, with many shareholders expressing strong frustration, labeling the deal a "robbery" given the company's debt-free balance sheet, significant cash, and a reported book value substantially exceeding the offer. Investors are actively discussing the fairness of the transaction, especially considering the CEO's controlling stake and the company's profitable operations within the healthcare imaging sector.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx (RARE) is trending due to the unexpected failure of its late-stage brittle-bone disease drug, setrusumab, to meet its primary efficacy endpoint in clinical trials, triggering a significant sell-off. This setback has sparked community discussion about the company's immediate outlook and broader biotech sector risks. However, many investors perceive the sharp decline as an overreaction, citing Ultragenyx's portfolio of approved therapies and other pipeline catalysts as a basis for potential recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Inspire Investing LLC Makes New Investment in Consolidated Water Co. Ltd. $CWCO

Inspire Investing LLC bought a new position in Consolidated Water Co. Ltd. (NASDAQ:CWCO - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC...

Consolidated Water (NASDAQ:CWCO) Shares Cross Above 200 Day Moving Average - Time to Sell?

Consolidated Water (NASDAQ:CWCO) Shares Pass Above 200-Day Moving Average - What's Next...

Here's Why Consolidated Water (CWCO) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

JPMorgan Chase & Co. Has $19.13 Million Position in Consolidated Water Co. Ltd. $CWCO

JPMorgan Chase & Co. raised its stake in Consolidated Water Co. Ltd. (NASDAQ:CWCO - Free Report) by 18.9% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC...

Consolidated Water (NASDAQ:CWCO) Director Sells $35,802.00 in Stock

Consolidated Water Co. Ltd. (NASDAQ:CWCO - Get Free Report) Director Wilmer Pergande sold 1,053 shares of the business's stock in a transaction on Monday, December 1st. The stock was sold at an...

Consolidated Water (NASDAQ:CWCO) Director Sells $145,091.25 in Stock

Consolidated Water Co. Ltd. (NASDAQ:CWCO - Get Free Report) Director Wilmer Pergande sold 4,299 shares of the company's stock in a transaction that occurred on Wednesday, December 3rd. The stock was...

Wilmer Pergande Sells 4,299 Shares of Consolidated Water (NASDAQ:CWCO) Stock

Consolidated Water Co. Ltd. (NASDAQ:CWCO - Get Free Report) Director Wilmer Pergande sold 4,299 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an...

Zacks Research Issues Pessimistic Forecast for CWCO Earnings

Consolidated Water Co. Ltd. (NASDAQ:CWCO - Free Report) - Equities researchers at Zacks Research cut their Q3 2026 earnings estimates for shares of Consolidated Water in a research note issued to...

Why Consolidated Water (CWCO) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Consolidated Water Co. Ltd. Announces Quarterly Dividend of $0.14 (NASDAQ:CWCO)

Consolidated Water Co. Ltd. (NASDAQ:CWCO) declared a quarterly dividend on Friday, November 21st. Investors of record on Friday, January 2nd will be given a dividend of 0.14 per share by the...

Consolidated Water Co. Ltd. engages in the development and operation of seawater desalination plants and water distribution systems. It operates through the following segments: Retail, Bulk, Services, and Manufacturing. The Retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Islands. The Bulk segment supplies potable water to government utilities in Grand Cayman and the Bahamas. The Services segment designs, constructs, and sells water infrastructure; and provides management and operating services to third parties. The Manufacturing segment focuses on the manufacture and service of custom and specialized water-related products applicable to commercial, municipal and industrial water production, supply, and treatment. The company was founded in 1973 and is headquartered in George Town, Cayman Islands.

CWCO
Consolidated Water Co. Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CWCO News

CWCOConsolidated Water Co. Ltd.